Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346860 | 0.86 | SLC6A4 (0.56) | SLC6A4MAOAMAOBALDH1A1 | |
| SCHEMBL16726626 | 0.80 | CA12 (0.52) | MAOAMAOBALDH1A1TSHRHTT | |
| SCHEMBL9793575 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOALMNA | |
| SCHEMBL10316183 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOATSHRLMNA | |
| SCHEMBL8591154 | 0.78 | SLC6A4 (0.50) | SLC6A4MAOAALDH1A1 | |
| SCHEMBL778040 | 0.78 | MAOA (0.45) | MAOAMAOBALDH1A1TSHRPOLB | |
| SCHEMBL424976 | 0.77 | MAOA (0.53) | MAOAMAOBALDH1A1TSHR | |
| SCHEMBL8985536 | 0.76 | PTGS1 (0.70) | — | |
| SCHEMBL13940796 | 0.76 | SLC6A4 (0.48) | SLC6A4MAOAALDH1A1 | |
| SCHEMBL169195 | 0.76 | SLC6A4 (0.48) | SLC6A4MAOAACHEALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2025-05-08 | — | — | US | disclosed |
| CN-113226321-B | Pyrazolyl compounds and methods of use thereof | 阿利安制药有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-20240297344-A1 | NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-114685331-B | Process for producing 1, 2-dithioethane compound | 华南理工大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-117945964-A | Synthesis method of aryl alkyl asymmetric thioether | 中国人民解放军军事科学院防化研究院 | 2024-04-30 | — | — | CN | disclosed |
| EP-3395795-B1 | MALONONITRILE OXIME ETHER COMPOUND AND USE THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2023-07-19 | — | — | EP | disclosed |
| EP-3814331-B1 | NOVEL LXR MODULATORS WITH BICYCLIC CORE MOIETY | ORSOBIO INC (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-115911573-A | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same | 三菱化学株式会社 | 2023-04-04 | — | — | CN | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| EP-1304325-A1 | 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-04-23 | — | — | EP | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| CN-1113241-A | Antifungal agent, and preparation method and intermediate thereof | EISAI CO LTD (JP) | 1995-12-13 | — | — | CN | disclosed |
| EP-0276124-B1 | PROSTAGLANDIN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-4981872-A | ANTIULCER | SANKYO COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0276124-A2 | Prostaglandin derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | SLC6A4 4359/4885MAOA 4213/4885MAOB 4179/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | SLC6A4 4610/4885MAOA 1504/4885MAOB 1572/4885 |
| US-20250145587-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | SLC6A4 4789/4885MAOA 3124/4885MAOB 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.